Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Devalingam Mahalingam

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
Journal of Gastrointestinal Oncology|March 23, 2018
Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to responseAri Rosenberg, Devalingam Mahalingam
Expert Opinion on Therapeutic Targets|October 15, 2008
Challenges in developing targeted therapy for pancreatic adenocarcinomaDevalingam Mahalingam, Francis Giles
Journal of Gastrointestinal Oncology|March 23, 2018
Immunotherapy in colorectal cancer: for the select few or all?Sukeshi Patel Arora, Devalingam Mahalingam
Oncotarget|December 20, 2017
Review: Oncolytic virotherapy, updates and future directionsChristos Fountzilas, Sukeshi Patel, Devalingam Mahalingam
Cancers|April 12, 2020
The Landscape of Targeted Therapies in TNBCElena Vagia, Devalingam Mahalingam, Massimo Cristofanilli
Cancer Investigation|October 14, 2015
Advanced Cancer Patients' Understanding and Perceptions of Phase I Clinical TrialsJamie Pawlowski, Laeeq Malik, Devalingam Mahalingam
Critical Reviews in Oncology/Hematology|May 16, 2024
Emerging targeted therapies and strategies to overcome resistance in biliary tract cancersTarik Demir, Carolyn Moloney, Devalingam Mahalingam
Cancers|March 13, 2025
Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal AdenocarcinomaTarik Demir, Carolyn Moloney, Devalingam Mahalingam
Cancers|August 3, 2019
Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC)Pedro Viveiros, Ahsun Riaz, Robert J Lewandowski, et al.
Leukemia & Lymphoma|June 10, 2010
Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agentsKevin Kelly, Ronan Swords, Devalingam Mahalingam, et al.
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Journal of Gastrointestinal Oncology|March 23, 2018
Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to responseAri Rosenberg, Devalingam Mahalingam
Expert Opinion on Therapeutic Targets|October 15, 2008
Challenges in developing targeted therapy for pancreatic adenocarcinomaDevalingam Mahalingam, Francis Giles
Journal of Gastrointestinal Oncology|March 23, 2018
Immunotherapy in colorectal cancer: for the select few or all?Sukeshi Patel Arora, Devalingam Mahalingam
Oncotarget|December 20, 2017
Review: Oncolytic virotherapy, updates and future directionsChristos Fountzilas, Sukeshi Patel, Devalingam Mahalingam
Cancers|April 12, 2020
The Landscape of Targeted Therapies in TNBCElena Vagia, Devalingam Mahalingam, Massimo Cristofanilli
Cancer Investigation|October 14, 2015
Advanced Cancer Patients' Understanding and Perceptions of Phase I Clinical TrialsJamie Pawlowski, Laeeq Malik, Devalingam Mahalingam
Critical Reviews in Oncology/Hematology|May 16, 2024
Emerging targeted therapies and strategies to overcome resistance in biliary tract cancersTarik Demir, Carolyn Moloney, Devalingam Mahalingam
Cancers|March 13, 2025
Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal AdenocarcinomaTarik Demir, Carolyn Moloney, Devalingam Mahalingam
Cancers|August 3, 2019
Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC)Pedro Viveiros, Ahsun Riaz, Robert J Lewandowski, et al.
Leukemia & Lymphoma|June 10, 2010
Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agentsKevin Kelly, Ronan Swords, Devalingam Mahalingam, et al.
Pageof 11